Trial Profile
A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Sep 2021
Price :
$35
*
At a glance
- Drugs Vilazodone (Primary) ; Fluoxetine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms VLZ-MD-22
- Sponsors AbbVie; Allergan; Forest Laboratories
- 22 Oct 2018 Status changed from recruiting to completed.
- 21 Feb 2018 Planned number of patients changed from 400 to 470.
- 21 Feb 2018 Planned End Date changed from 1 Jun 2017 to 8 Sep 2018.